Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

Table 1 Clinical characteristics of all sets

Characteristic	Training (n = 712)	Test (n = 168)	FNA (n = 256)	FNA subgroup (n = 132)
Age
Median	62	56	50	50
Range	23-89	30-69	23-85	23-77
T stage	(n = 542)	(n = 166)	(n = 255)	(n = 132)
Tis	6	0	5	0
T1	165	49	22	14
T2	268	97	135	76
T3	37	20	42	24
T4	66	0	51	18
N stage	(n = 541)	(n = 166)	(N = 255)	(n = 132)
N0	280	0	102	47
N1	198	11	84	52
N2	39	75	15	13
N3	24	80	54	20
Stage	(n = 541)	(n = 166)	(n = 254)	(n = 132)
0	6	0	2	0
I	105	1	8	4
II	315	83	141	79
III	94	82	86	49
IV	21	0	18	0
Histology	(n = 576)	(n = 166)	(n = 255)	(n = 132)
Ductal	446	132	212	113
Other	130	34	43	19
Grade	(n = 457)	(n = 132)	(n = 251)	(n = 132)
1	65	29	12	8
2	149	69	72	39
3	243	34	167	85
Estrogen Receptor Status	(n = 709)	(n = 165)	(n = 255)	(n = 132)
Positive	447	126	149	79
Negative	262	39	106	53
Progesterone Receptor Status	(n = 709)	(n = 168)	(n = 255)	(n = 132)
Positive	336	82	108	56
Negative	373	86	147	76
HER2 Status	(n = 709)	(n = 128)	(n = 254)	(n = 132)
Positive	142	18	53	121
Negative	567	110	201	11
Clinical Subtype	(n = 709)	(n = 128)	(n = 254)	(n = 132)
Hormone receptor-positive	383	106	139	80
HER2-positive	142	40	53	11
Triple receptor-negative	184	22	62	41
Systemic Treatment	(n = 598)	(n = 168)	(n = 255)	(n = 132)
Adjuvant hormonal therapy	341	97	136	78
(Neo)Adjuvant chemotherapy	188	71	253	132
CMF-based	188	71	0	0
Anthracycline-based	0	0	21	0
Taxane-based	0	0	14	0
Anthracycline and Taxane-based	0	0	184	132
Trastuzumab-based	0	0	34	0
None	111	0	2	0

Note that numbers may not add up to the total in each category due to missing data. Tumors are assigned to the HR-positive group only if they are HER2-negative; tumors that are HER2-positive and HR-positive are classified in the HER2-positive group. FNA: Fine needle aspirates.

ISSN: 1559-0275